Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

Dubbyy Dec. 27 at 2:06 PM

$OVID https://uk.finance.yahoo.com/news/promising-penny-stocks-watch-december-120454944.html

0 · Reply

Dubbyy Dec. 27 at 9:13 AM

$OVID Check out this article from TipRanks | CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts | https://tipranks.onelink.me/WJho/jthvqtai

0 · Reply

PossibilityP Dec. 27 at 5:34 AM

$OVID Investor attention is skewing toward repeatable operating performance instead of aspirational projections. Efficiency gains must convert into measurable results. Durability across environments would extend investor horizons. Sentiment should follow confirmed results rather than headlines.

0 · Reply

StockConsultant Dec. 24 at 2:25 PM

$OVID Therapeutics stock with a few strong days, watch for a top of range breakout

0 · Reply

QuantKingpin Dec. 24 at 10:02 AM

$OVID Investor conviction will hinge on whether resource allocation supports scalability without eroding optionality. Failure to demonstrate progress would likely keep valuation capped.

0 · Reply

SuperGreenToday Dec. 23 at 10:56 PM

$OVID Share Price: $1.80 Contract Selected: Jul 17, 2026 $0.5 Calls Buy Zone: $1.10 – $1.37 Target Zone: $1.77 – $2.16 Potential Upside: 51% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

michaelhearn Dec. 23 at 1:40 PM

$OVID nice volume buying

0 · Reply

REDWIR Dec. 22 at 9:14 PM

$OVID boom!! Nice one 20 percent day

0 · Reply

OfficialStocktwitsUser Dec. 22 at 6:08 PM

$OVID RSI: 59.20, MACD: 0.0233 Vol: 0.11, MA20: 1.59, MA50: 1.50 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Tonydarien Dec. 22 at 5:18 PM

$OVID so happy I added 3,000 shares @ $1.28. Looking to add more at a pullback if end of year profit taking happens.

0 · Reply

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 2, 2025, 7:00 AM EST - 25 days ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Nov 12, 2025, 7:00 AM EST - 6 weeks ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Oct 3, 2025, 12:52 PM EDT - 3 months ago

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 7:05 AM EDT - 3 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:00 AM EDT - 3 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Jul 23, 2025, 8:30 AM EDT - 5 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jun 25, 2025, 8:00 AM EDT - 6 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 13, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 10 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 10 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 11 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Dubbyy Dec. 27 at 2:06 PM

$OVID https://uk.finance.yahoo.com/news/promising-penny-stocks-watch-december-120454944.html

0 · Reply

Dubbyy Dec. 27 at 9:13 AM

$OVID Check out this article from TipRanks | CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts | https://tipranks.onelink.me/WJho/jthvqtai

0 · Reply

PossibilityP Dec. 27 at 5:34 AM

0 · Reply

StockConsultant Dec. 24 at 2:25 PM

$OVID Therapeutics stock with a few strong days, watch for a top of range breakout

0 · Reply

QuantKingpin Dec. 24 at 10:02 AM

$OVID Investor conviction will hinge on whether resource allocation supports scalability without eroding optionality. Failure to demonstrate progress would likely keep valuation capped.

0 · Reply

SuperGreenToday Dec. 23 at 10:56 PM

0 · Reply

michaelhearn Dec. 23 at 1:40 PM

$OVID nice volume buying

0 · Reply

REDWIR Dec. 22 at 9:14 PM

$OVID boom!! Nice one 20 percent day

0 · Reply

OfficialStocktwitsUser Dec. 22 at 6:08 PM

0 · Reply

Tonydarien Dec. 22 at 5:18 PM

$OVID so happy I added 3,000 shares @ $1.28. Looking to add more at a pullback if end of year profit taking happens.

0 · Reply

jacksparo Dec. 22 at 4:48 PM

$OVID Shared last night in my email but it moved big today … Well it is ok at least my theory about it was right will have a better luck 🍀 next time 📈📈!

0 · Reply

lucabrix Dec. 22 at 4:01 PM

$OVID mind the 1.80 resistance!

0 · Reply

dl42 Dec. 22 at 3:55 PM

$OVID i’m about 3/4 of where I want to be w OVID, plan was to buy more this morning but i’ll wait. I figured this was going to happen based on some people w/ lots of followers on X mentioning OVID this weekend.

0 · Reply

notreload_ai Dec. 22 at 3:38 PM

$ZBIO , $SPRB , $CNTX , $OVID ... Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics. https://notreload.xyz/biotech-stocks-update-zbio-sprb-cntx-ovid-ratings/

0 · Reply

JarvisFlow Dec. 22 at 3:15 PM

LifeSci Capital updates rating for Ovid Therapeutics ( $OVID ) to Outperform, target set at 4.

0 · Reply

Dubbyy Dec. 22 at 2:49 PM

$OVID Check out this article from TipRanks | Ovid Therapeutics initiated with an Outperform at LifeSci Capital | https://tipranks.onelink.me/WJho/owi7bt0r

0 · Reply

Dubbyy Dec. 22 at 2:34 PM

$OVID bullish

0 · Reply

stockinghead Dec. 22 at 1:25 PM

$OVID morning looking strong

0 · Reply

Dubbyy Dec. 22 at 12:04 PM

$OVID Check out this article from TipRanks | Ovid Therapeutics: Positive KCC2 Platform Progress and Underappreciated Pipeline Optionality Support Reiterated Buy Rating | https://tipranks.onelink.me/WJho/eerytuvl

0 · Reply

JarvisFlow Dec. 22 at 11:33 AM

HC Wainwright & Co. has adjusted their stance on Ovid Therapeutics ( $OVID ), setting the rating to Buy with a target price of 2.

0 · Reply

stockinghead Dec. 22 at 1:39 AM

$OVID loading up tomorrow.

0 · Reply

REDWIR Dec. 20 at 2:26 PM

$OVID this is a really great buy and hold . This is going to explode one day and everyone holding will deserve it .

0 · Reply

Market Cap	126.76M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,636.84%
Debt to Equity Ratio	0.00

Volume	857,000
Avg Vol	1,688,480
Day's Range	N/A - N/A
Shares Out	71.21M
Stochastic %K	84%
Beta	0.04
Analysts	Strong Sell
Price Target	$4.38